Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer
- Citation:
- Cancer Res vol 76 (4 Suppl) P1-14-02
- Meeting Instance:
- SABCS 2015
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2954
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA76001
- Corr. Author:
- Aman U. Buzdar
- Authors:
- Aman U. Buzdar Vera J. Suman Funda Meric-Bernstam Ann M. Leitch Matthew J. Ellis Judy C. Boughey Gary W. Unzeitig Melanie E. Royce Michael S. Ewer Kelly K. Hunt
- Networks:
- LAPS-MN026, LAPS-TX011, LAPS-TX035, NEWMEXICO, TX041, TX190
- Study
- ACOSOG-Z1041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: